Search

Displaying results 1841 - 1850 of 8970 in total
  1. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.

    Categories: Agents for Dermatitis, Excluding Corticosteroids
  2. Drug

    Darunavir

    go.drugbank.com/drugs/DB01264
    ApprovedInvestigational

    [L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection. … [L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.

    Categories: Compounds used in a research, industrial, or household setting
  4. Indication

    Ovulation Absent

    go.drugbank.com/conditions/DBCOND0140456
    Drugs: Letrozole
    Synonyms: Female infertility due to anovulation (disorder)
  5. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.

    Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, BERIPLEX P/N 500 POWDER FOR SOLUTION FOR INJECTION
  6. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,

    Categories: Agents for Dermatitis, Excluding Corticosteroids
  7. Indication

    Acute Non-Lymphocytic Leukemia

    go.drugbank.com/conditions/DBCOND0038781
    Drugs: Tioguanine
    Synonyms: Acute myeloid leukemia, no International Classification of Diseases for Oncology subtype
  8. Indication

    Cutaneous Melanoma

    go.drugbank.com/conditions/DBCOND0040978
    Drugs: Ipilimumab
    Synonyms: Malignant melanoma, no International Classification of Diseases for Oncology subtype
  9. Indication

    Leukemias

    go.drugbank.com/conditions/DBCOND0035632
    Drugs: Betamethasone · Bupivacaine · Hydrocortisone · Hydrocortisone succinate · Methylprednisolone · Methylprednisolone hemisuccinate +2 more
    Synonyms: Leukemia, no International Classification of Diseases for Oncology subtype
  10. Indication

    Melanoma

    go.drugbank.com/conditions/DBCOND0020306
    Drugs: Dabrafenib · Nivolumab · Peginterferon alfa-2b · Trametinib
    Synonyms: Malignant melanoma, no International Classification of Diseases for Oncology subtype